Mike is a Senior Advisor on the Life Sciences team and an experienced executive in developing therapeutics for oncology.
Mike joined the Frazier Life Sciences team as a Senior Advisor in April 2019. He is currently the
Chief Medical Officer of Unum Therapeutics Inc., a Cambridge, MA cell and gene therapy company developing autologous engineered T cell products for the treatment of cancer.
Prior to Unum, Mike spent several years at Takeda/Millennium, where he was Senior Vice President and Head of the Oncology Therapy Area Unit, accountable for strategic and operational oversight of the oncology research and development portfolio globally. Prior to Takeda/Millennium, Mike was Group Vice President and the Global Therapeutic Area Head, Transplant and Oncology, at Genzyme Corporation where he was responsible for clinical development of the transplant and oncology portfolio and a member of the Transplant and Oncology Business Unit Management Team. Following Sanofi’s acquisition of Genzyme, Mike joined Sanofi Oncology as Head, Personalized Medicine and Companion Diagnostics.
Mike has been a faculty member of the Harvard Medical School since 1996, and is an associate physician at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He received both his B.A. and M.D. from Northwestern University.
Northwestern University (B.A. and M.D.)